We developed a novel strategy for treatment of Leber hereditary optic neuropathy (LHON) caused by a mutation in the nicotinamide adenine dinucleotide dehydrogenase subunit IV (ND4) mitochondrial gene.
Supplemental content at jamaophthalmology.com sion of the mitochondrial gene (ND4 in this case) was expressed in the nucleus, translated on c ytoplasmic polyribosomes, and imported into the mitochondria with the addition of an N-terminal mitochondrial targeting sequence. [5] [6] [7] [8] In studies more than a decade ago, expression of the allotopic ND4 gene in G11778A LHON cells corrected defective adenosine triphosphate (ATP) synthesis. 9 Next, this technology was used to generate a mouse model of LHON by delivering a nuclear-encoded version of the mutant human ND4 that induced swelling of the optic nerve head, followed by a progressive demise of RGCs and their axons. 10 In contrast, expression of the wild-type (WT) allotopic ND4 produced no abnormalities in visual function or pathologic changes in the retina or optic nerve. 11 Herein we describe the efficacy and safety of the vector proposed for the treatment of LHON caused by mutated G11778A mitochondrial DNA.
Methods

Construction of the Viral Vector and Intraocular Injections
The WT and mutant (MT) allotopic ND4FLAG fusion genes containing the mitochondrial targeting sequences and epitope tag were constructed and packaged into adeno-associated viral (AAV) virions as previously described. 12, 13 This process is described in detail in the Supplement (eMethods) eyes. Seventy-two hours after these injections, singlestranded AAV2 (ssAAV2)-MT-ND4FLAG (G11778A) (1.02 × 10 12 vg/mL) was injected into both eyes. In another group of mice (n = 10), 1 μL of ssAAV2-WT-ND4FLAG (6.80 × 10 12 vg/mL) was injected into the right eye and 1 μL of ssAAV2-GFP was injected into the left eye. Seventy-two hours after these injections, 1 μL of ssAAV2-MT-ND4FLAG (G11778A) was injected into both eyes. A summary of the use of animals in our experiments is provided in the Supplement (eTable).
To test the safety of the vector for a phase 1 clinical trial, 3 rhesus macaques (1 male and 2 female, aged 3-7 years) were injected with the test article scAAV2(Y444,500,730F)-P1ND4v2 that lacked the FLAG epitope. Two additional animals were injected with scAAV2-GFP (triple Y-F capsid), driven by the same promoter (small cytomegalovirus chicken β-actin [smCBA]) as the P1ND4v2 test article.
Electrophysiological Examinations
Pattern electroretinograms (PERGs) were obtained in mice at 1, 6, and 12 months after the viral injection as previously described.
14 Rhesus macaques underwent assessment by multifocal electroretinography before intravitreal injection and at 1 and 3 months after vector injection.
Imaging
The mouse retina was imaged at 1, 3, 6, and 12 months after AAV injection using optical coherence tomography (OCT) (Bioptigen, Inc) as described previously. 15 Rhesus macaques underwent assessment by ophthalmologic examination, color retinal fundus photography (FF450; Zeiss), and OCT (Heidelberg Spectralis; Heidelberg Engineering, Inc) before intravitreal injection and at 5 days, 1 and 2 weeks, and 1 and 3 months after vector injection. For 1 animal, retinal imaging was also done at 4 months.
Expression Analyses
For expression studies, mice were humanely killed 1, 3, and 7 days after the viral injections. The eyes were removed and underwent immunohistochemical processing as previously described. 16 Because our goal is to treat patients with LHON, we also tested for transgene expression in 2 normal human eyes that were surgically removed for control of periocular spread of cancers. In rhesus macaque eyes, retinal longitudinal sections (8 μm) were obtained. The FLAG-positive cells (right eyes), GFPpositive cells (left eyes), and Thy1.2-positive RGCs (both eyes) were counted. Images of the optic nerves from the right and left eyes were analyzed for diameters.
Mice receiving the double viral injections were killed humanely 1 year (scAAV) or 6 months (ssAAV) after injections. The eyes and optic nerves underwent immunohistochemical processing and electron microscopic examination as previously described. 16 Primates injected with scAAV-P1ND4v2 (triple Y-F capsid) were killed humanely 3 months after scAAV injections. Total RNA was isolated from the retinas and optic nerves of injected eyes and uninjected controls. Sequencing of reverse transcription polymerase chain reaction products was performed using a commercially available cycle sequencing kit (ABI Prism BigDye Terminator kit; Applied Biosciences).
One year after intravitreal viral injections, 5 mice were killed humanely and the optic nerves were immediately dissected for measurements of the rate of ATP synthesis as previously described. 9 Fragmentation of DNA characteristic of apoptosis in mice retinal whole mounts 1 year after AAV injections (n = 3) was monitored by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling.
Statistical Analysis
We used the 2-tailed, unpaired t test to compare the transduction efficiency of right eyes inoculated with scAAV2-WT-ND4 (triple Y-F capsid) and RGCs identified by Thy1.2 positivity. We also used the 2-tailed, unpaired t test in rescue studies to compare the right eyes inoculated with scAAV2-WT-ND4FLAG (triple Y-F capsid) plus ssAAV2-MT-ND4FLAG and the control (left) eyes receiving scAAV2-GFP plus ssAAV2-MT-ND4FLAG. P ≤ .05 was considered significant. 
Results
Expression of WT Allotopic Human ND4 in Mice
Expression of WT Allotopic ND4 in Ex Vivo Human Eyes
Confocal microscopy of the ex vivo human retinal flat mounts focused on the RGC layer revealed 4',6-diamidino-2-phenylindole (DAPI)-labeled cell nuclei ( Figure 1A ) with ND4FLAG expression ( Figure 1B ) surrounding the nucleus of almost all RGCs ( Figure 1C ). At higher magnification, human RGC ( Figure 1D ) expression of ND4FLAG ( Figure 1E ) was perinuclear ( Figure 1F ). At high power, ND4FLAG expression was punctate ( Figure 1G ), as were mitochondria labeled with a bona fide mitochondrial marker voltage-dependent anion channel/ porin ( Figure 1H ) that colocalized with ND4FLAG ( Figure 1I ). Quantitative analysis revealed that, with intravitreal injection of more than 10 11 vg, 84% of cells in the RGC layer expressed ND4FLAG ( Figure 1J ).
Transcription of MT and WT Allotopic Human ND4 in Mice
Next, we tested for rescue of optic neuropathy in a mouse model of LHON induced by coinjection of AAV virions containing the MT allotopic ND4 allele. 18 To demonstrate that MT and WT human ND4 are expressed in mouse eyes coinjected with ssAAVs containing the disease-inducing MT R340H ND4 and with the rescue WT human ND4, we performed reverse transcription polymerase chain reaction of RNA isolated from 10 mice that received injections of the MT and WT alleles into both eyes. We found human ND4 messenger RNAs in the retina and optic nerves, but not in the heart ( Figure 2A ). Gene sequencing of the amplicons showed the presence of MT R340H
ND4 (CAC-histidine) ( Figure 2B ) and WT R340R (AGGarginine) complementary DNA ( Figure 2C ), thus confirming transcription of human MT and WT ND4 alleles in doubleinjected eyes. Previous studies 11, 12 have demonstrated that the MT ND4 allele induces optic neuropathy in mice and that WT human ND4 is safe and does not cause visual loss in mice. Our next step was to determine whether the WT human ND4 would provide rescue of visual dysfunction induced by the MT human ND4 allele.
Rescue of Visual Loss by WT Allotopic Human ND4
Using the PERG, a sensitive measure of visual potential and RGC function, 19 we recorded signals in mice 1, 6, and 12 months after intraocular injections of rescue vector scAAV2-WT-ND4FLAG (packaged with triple Y-F VP3 capsid modifications) and the disease-inducing ssAAV2-MT-ND4FLAG into the right eyes. The left eyes received the disease-inducing AAV-MT-ND4FLAG followed by scAAV containing only GFP (ie, mock rescue) that had been demonstrated to have no adverse effects on the optic nerve. 16 Preservation of visual function was assessed by comparisons between treated and mock-treated eyes and comparison with PERG recordings of healthy mice receiving no injection (controls) belonging to the same age groups as AAV-injected mice. Seventeen experimental mice and 14 controls contributed data to this analysis. One month after intraocular injections, the mean (SE) PERG amplitudes in the mock-rescued left eyes receiving scAAV2-GFP along with the disease-inducing ssAAV2-MT-ND4 diminished (18.1 [2.5] μV) relative to age-matched controls (27.4 [2.8] μV; P = .02). The mean (SE) PERG amplitudes in these left eyes significantly worsened at 6 months (16.8 [1.95] μV; P = .006) and 1 year (12.9 [3.2] μV; P = .02) after injection. However, rescued right eyes compared with the age-matched controls showed no significant differences at any point examined ( Figure 2D ). For PERG amplitudes, analysis of variance with random effects to account for correlated measurements of the same animals over time found a statistically significant difference between right eyes rescued with WT allotopic ND4 (mean [SE], 18.668 [0.979] μV) and left eyes mock-treated with GFP (15.254 [1.052] μV; P = .02). The mean (SE) of left and right eyes together in the controls was 23.703 (1.687) μV. Amplitudes for WT ND4-injected right eyes were reduced relative to those of the controls (P = .01). Values of the GFP-treated left eyes were also reduced relative to those of controls (P < .001). In addition, we found a statistically significant difference in PERG latency between the rescued right eyes (mean [ Figure 2H ) months after injection revealed no significant differences of the RGC and inner plexiform layers. In contrast, the contralateral mocktreated eyes exhibited initial swelling of the optic nerve head, also seen in patients with LHON and acute visual loss, and of the adjacent RGC and inner plexiform layers at 1 month ( Figure 2I ), followed by progressive thinning of these layers at 3 ( Figure 2J ) and 6 ( Figure 2K ) months after injection and almost complete loss ( Figure 2L ) in some eyes examined 1 year after injection. Differences between the right eyes undergoing WT ND4 rescue and left eyes undergoing mock GFP treatment were statistically significant at 6 (P = .02) and 12 (P = .005) months after injection ( Figure 2M ). Thus, WT allotopic ND4 ameliorated progressive loss of cells in the RGC layer.
Prevention of RGC Loss by WT Allotopic ND4: Histopathologic Studies
One year after intraocular injections, light microscopy showed no thinning of the inner retina in right eyes rescued from the disease-inducing R340H MT allotopic ND4 by coinjection of the WT allotopic ND4 delivered by scAAV (triple Y-F capsid) ( Figure 3A ). Higher magnification revealed no cell loss in the RGC layer ( Figure 3B and C) . In contrast, left eyes mock rescued with GFP from the adverse effects of the R340H MT allotopic ND4 had marked loss of the inner retina ( Figure 3D ) with substantial demise of RGCs ( Figure 3E and F). Quantitative 
Prevention of Optic Nerve Atrophy by WT Allotopic ND4
Gross dissection specimens of animals killed humanely 1 year after rescue with WT ND4 packaged with the triple Y-F capsidmodified scAAV showed striking differences between eyes. Treated right optic nerves were of normal caliber along their entire length from the back of the eye to the optic chiasm ( Figure 4A and B) . In contrast, the left optic nerves of these animals were markedly atrophic, with a 40% loss in diameter ( Figure 4C -E) that was highly significant relative to the treated right optic nerves (P = 1.3 × 10 −12 ). Transmission electron micrographs showed few remaining fibers, some with degenerating axon profiles in mock-treated optic nerves even 1 year after intraocular injections ( Figure 5A ), when axonal loss and fibers with thin myelin lamellae were prominent ultrastructural findings ( Figure 5B ). In contrast, axons of rescued optic nerves were relatively preserved and numerous ( Figure 5C .
complex I-dependent ATP synthesis rates that were not significantly different from those of controls receiving no injection. Thus, the degree of oxidative phosphorylation loss induced by the R340H MT ND4 allele was suppressed by WT allotopic ND4.
Suppression of RGC Apoptosis by WT Allotopic ND4
Because defective respiration is linked to cell death, we tested for apoptosis next. Retinas from eyes rescued with WT allotopic 
Incorporation of Allotopic ND4 Into Respiratory Complexes
Next, we looked for incorporation of WT allotopic ND4 into respiratory complexes. Antibodies against NDUFA9 (hydroxyl- as we also see herein. These findings further support earlier studies using immunoprecipitation of complex I subunits 10, 11 identified by mass spectroscopy that allotopic ND4 forms respiratory complexes.
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Safety in Nonhuman Primates
Next, we tested the safety of WT allotopic ND4 for human gene therapy using rhesus macaques. In 1 animal, fundus photographs obtained before injection ( Figure 6A 
Discussion
An effective and safe delivery system is essential for human mitochondrial ND4 gene therapy. This delivery system can be achieved by using AAV vectors. Recombinant Self-complementary vectors that contain positive and negative strands 35-37 and tyrosine-to-phenylalanine modifications in the capsid proteins increase the speed and efficiency of transgene expression, which is crucial to intervention in LHON with its characteristic apoplectic onset of permanent visual loss.
38-42
To develop a clinically relevant vector for gene therapy for LHON, we first tested the standard ssAAV vector. Previous studies 9, 16 had demonstrated that this delivery system carrying the WT allotopic ND4 rescued defective ATP synthesis of LHON cells. In most cases of human LHON, the pathogenic G11778A mitochondrial DNA mutation is homoplasmic, that is, no WT ND4 is present except in 14% of cases in which the mutation exists in a heteroplasmic condition. 43, 44 In our mouse model generated by intravitreal injection of an allotopic R340H MT ND4 with ssAAV, expression of MT human ND4 initially induced swelling of the optic nerve head, followed by progressive demise of RGCs and their axons. Unlike the human condition, these hallmarks of human LHON occurred even in the presence of endogenous mouse ND4. 10 As such, we found this dominant model system much more difficult to rescue than human LHON cells. A highly efficient triple Y444F-Y500F-Y730F-modified scAAV vector was needed to rescue visual loss and optic neuropathy caused by the allotopic R340H MT ND4 in the mouse model.
Conclusions
Previous studies 11, 12 have shown that expression of the WT allotopic ND4 produced no abnormalities in visual function or pathologic changes in the vitreous, retina, or optic nerve of rodents. Our allotopic WT human ND4 vector produced only mild transient inflammation in a single monkey that was also seen in another study. 45 Taken with the absence of structural or functional abnormalities on OCT and multifocal electroretinograms in eyes that most closely resemble those of humans, these findings suggest that our good manufacturing practice gene therapy vector is safe for testing in a phase 1 clinical trial for G11778A LHON. Furthermore, expression of WT allotopic ND4 of the normal homologue of the defective R340H ND4 gene into the mitochondria of the mouse retina preserved vision, restored defective ATP synthesis, and prevented apoptosis of RGCs and demise of optic nerve axons for almost the entire lifespan of the laboratory mouse. Because the human vector to be used for the clinical trial could not contain an epitope tag for immunodetection, we tested expression of GFP delivered by the triple Y-F capsid-modified scAAV in 2 nonhuman primates, in which it expressed in RGCs of the macula, which are affected in patients with LHON. Our findings complement previous studies demonstrating that the to show efficacy in the primary outcome measure of improving vision in patients with LHON. The absence of Retinal fundus images of the right eye of a rhesus monkey before injection (A) of self-complementary adeno-associated viral vector-P1ND4v2 (AAV) and 5 days (B), 1 week (C), 2 weeks (D), 1 month (E), 2 months (F), and 3 months (G) after injection show that the macula and optic disc remained normal and similar to the uninjected left eye (H-N). The AAV-injected right eye of a second animal is normal at baseline (O), and at 5 days (P), 1 week (Q), and 2 weeks (R) after injection, but developed mild haze from vitritis at 1 month postinjection (S) that cleared at 2 months (T) to 3 months (U) after injection. The uninjected left eye of the same animal (control) was normal before injection of the opposite eye (V) and at all time points after injection (V through AB). 
